Various membrane receptors overexpressed in cancers are potential targets for diagnosis and therapy. These receptors include folate receptor, gastrin-releasing peptide receptor (GRPR), somatostatin receptor type 2 (Sstr2), C-X-C chemokine receptor type 4 (CXCR4) and melanocortin 1 receptor (MC1R). Our lab is actively developing radiopharmaceuticals targeting these receptors to improve diagnosis and radiotherapy of cancer.
Development of Receptor-targeting Radiopharmaceuticals
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.